Sector
PharmaceuticalsOpen
₹174.55Prev. Close
₹175.36Turnover(Lac.)
₹218.31Day's High
₹178.99Day's Low
₹172.652 Week's High
₹240.752 Week's Low
₹92.05Book Value
₹43.79Face Value
₹2Mkt Cap (₹ Cr.)
4,405.32P/E
218EPS
0.8Divi. Yield
0Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 49.89 | 49.89 | 58.81 | 49.67 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,037.34 | 1,008.48 | 982.28 | 979.84 |
Net Worth | 1,087.23 | 1,058.37 | 1,041.09 | 1,029.51 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 265.45 | 227.33 | 106 | 90.71 |
yoy growth (%) | 16.77 | 114.45 | 16.85 | -77.01 |
Raw materials | -108.86 | -113.04 | -79.37 | -72.52 |
As % of sales | 41.01 | 49.72 | 74.87 | 79.94 |
Employee costs | -22.41 | -17.09 | -11.85 | -17.9 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 43.44 | 22.81 | 1.82 | -15.16 |
Depreciation | -9.12 | -8.95 | -3.66 | -3.25 |
Tax paid | -8.77 | -1.47 | -2.86 | 0 |
Working capital | 33.97 | -80.01 | -110.8 | 56.46 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 16.77 | 114.45 | 16.85 | -77.01 |
Op profit growth | 58.69 | -220.94 | -39.83 | -186.01 |
EBIT growth | 65.64 | 1,156.67 | -115.03 | -154.81 |
Net profit growth | 50.47 | -94.74 | -33,86,825 | -100.11 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 | 1,179.24 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 | 1,179.24 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 10.96 | 6.39 | 10.85 | 8.36 | 10.09 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,819 | 157.92 | 4,35,359.33 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,782.35 | 84.51 | 1,55,255.32 | 518 | 0.51 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.6 | 59.99 | 1,20,250.73 | 634.43 | 0 | 2,529.74 | 269.23 |
Cipla Ltd CIPLA | 1,475.75 | 28.17 | 1,19,240.17 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,399.45 | 70.76 | 1,15,763.45 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec. & Independent Dir.
Kausalya Santhanam
Joint Managing Director
Sharat Narasapur
Non-Exec & Non-Independent Dir
Neeraj Bharadwaj
Non-Exec & Non-Independent Dir
Gregory John Andrews
Non-Exec & Non-Independent Dir
Fabian Kausche
Chairman & Independent Directo
Kamal K Sharma
Non-Exec. & Independent Dir.
Milind Sarwate
Managing Director & CEO
N Rajaram
Non Executive Director
Hari Babu Bodepudi
Company Sec. & Compli. Officer
PHILLIP TROTT
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sequent Scientific Ltd
Summary
Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself. The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on Nov 12, 2003.
Read More
The Sequent Scientific Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹176 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sequent Scientific Ltd is ₹4405.32 Cr. as of 24 Dec ‘24
The PE and PB ratios of Sequent Scientific Ltd is 218 and 3.94 as of 24 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Sequent Scientific Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sequent Scientific Ltd is ₹92.05 and ₹240.7 as of 24 Dec ‘24
Sequent Scientific Ltd's CAGR for 5 Years at 19.12%, 3 Years at 3.45%, 1 Year at 47.42%, 6 Month at 48.38%, 3 Month at -2.08% and 1 Month at -13.40%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice